Resmetirom Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 80 mg ,100 mg
Reference Brands: Rezdiffra (USA)
Category:
Gastrointestinal Drugs
Resmetirom is available in Tablets
and strengths such as 80 mg ,100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Resmetirom is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Resmetirom can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Resmetirom, marketed under the brand name Rezdiffra, is an innovative oral medication developed for the treatment of non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). It is specifically indicated for adult patients with moderate to advanced liver fibrosis, corresponding to fibrosis stages F2 to F3, and is prescribed in combination with diet and exercise.
Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist and is structurally related to the endogenous thyroid hormone triiodothyronine (T3). By selectively activating THR-β receptors in the liver, resmetirom helps regulate lipid metabolism, reduce hepatic fat accumulation, and improve inflammatory and fibrotic processes associated with MASH. Its liver-targeted mechanism allows therapeutic benefits while minimizing systemic thyroid-related effects.
The drug represents a significant advancement in the management of MASH, a progressive fatty liver disease that can lead to cirrhosis, liver failure, and increased cardiovascular risk if left untreated. As the first FDA-approved oral therapy specifically targeting the underlying metabolic drivers of MASH, resmetirom offers a disease-modifying approach rather than symptomatic relief alone, making it a valuable option in modern hepatology treatment strategies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing